NUSINERSEN
nusinersen 12 mg/5 mL intrathecal injection, 5 mL vial
NUSINERSEN (13084P)
13084P
Manner of administration:Injection
Restriction
Indication: Symptomatic type IIIB/IIIC spinal muscular atrophy (SMA)
Treatment phase: Continuing/maintenance treatment in a child or adult, but where treatment was initiated
during childhood
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 1 | # of repeats: 0 | DPMQ: $104,500.00 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Spinraza | |||||